---
title: "Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Pharmacology questions"
description: "Pharmacology questions on Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does TRODELVY work (mechanism of action)? How is TRODELVY metabolized? What is the half-life of TRODELVY? What are the ingredients in TRODELVY? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Pharmacology questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Trodelvy](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)

## Mechanism

<a id="trodelvy-mechanism"></a>

### How does TRODELVY work (mechanism of action)?

> “Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that 
> recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody 
> by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is 
> internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and 
> prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and 
> cell death.”

Source: [TRODELVY: Prescribing information, page 24, captured 2026-11-08](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf#page=24)

> “Once internalized, the CL2A linker may allow the release of SN-38 directly into Trop-2–expressing cells, including tumor cells, and then into the tumor microenvironment and nearby tumor cells—known as the bystander effect.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/moa#:~:text=Once%20internalized%2C%20the%20CL2A%20linker,cells%E2%80%94known%20as%20the%20bystander%20effect.)

> “The mechanism of action, including the bystander effect, is suggested based on preclinical data, which may not correlate with clinical outcomes.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/moa#:~:text=The%20mechanism%20of%20action%2C%20including,not%20correlate%20with%20clinical%20outcomes.)

## Pharmacokinetics

<a id="trodelvy-metabolism"></a>

### How is TRODELVY metabolized?

> “No metabolism studies with sacituzumab govitecan-hziy were conducted. SN-38 (the small molecule moiety of 
> sacituzumab govitecan-hziy) is metabolized via UGT1A1. The glucuronide metabolite of SN-38 (SN-38G) was detectable 
> in the serum of patients.”

Source: [TRODELVY: Prescribing information, page 25, captured 2026-11-08](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf#page=25)

<a id="trodelvy-half-life"></a>

### What is the half-life of TRODELVY?

> “The median elimination half-life (t1/2) of sacituzumab govitecan-hziy is 6.5 days and free SN-38 is 22 hours. The terminal 
> half-life (t1/2) of sacituzumab govitecan-hziy is 6.7 days (23%) and the apparent half-life (t1/2) of free SN-38 is 24 hours 
> (50%). The clearance of sacituzumab govitecan-hziy is 0.13 L/h (20%).”

Source: [TRODELVY: Prescribing information, page 25, captured 2026-11-08](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf#page=25)

## Components

<a id="trodelvy-ingredients"></a>

### What are the ingredients in TRODELVY?

> “Each single-dose vial of TRODELVY delivers 180 mg sacituzumab govitecan-hziy, 71.7 mg 2-(N-morpholino) ethane 
> sulfonic acid (MES), 1.8 mg polysorbate 80 and 153.99 mg trehalose.”

Source: [TRODELVY: Prescribing information, page 24, captured 2026-11-08](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf#page=24)

## Related pages
- [Medical information: Trodelvy (sacituzumab govitecan-hziy): Metastatic triple-negative breast cancer](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/guidelines)
